We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.
View, monitor and analyze all your compliance data in one place.
Multichannel solution to better manage consent, disputes and pre-disclosure review.
Market and competitor intelligence at your fingertips.
What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?
What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?
Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.
The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.SIGN UP AS AN EXPERT
Efficiency and Foresight: The qordata Advantage For Zimmer Biomet
For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.DOWNLOAD
Helping thousands of people and companies communicate and work better.
qordata Releases Open Payments Data 2016
Princeton, New Jersey: qordata has released Open Payments Data 2016 less than 24 hours after the publication of 11.96 million financial transactions, (US $ value 8.18 billion) on the CMS Website.READ FULL STORY
Thought Leadership —Transparency, Insights And Disclosure
Taking physician consent has been there for a while under the EU transparency disclosure requirements. With the GDPR coming into effect soon, the need to acquire consent has now become more intense and with a much broader scope. Now, the scope applies to: Employees Patients HCPs and others For not just transparency disclosure reporting, but also: Clinical trials data ERP and CRM data Expense reporting and financial data HRMS and other kinds of data Lawfulness of processing according to Article 6(1) will be considered true if (unless there are exceptions): the data subject has given consent to the processing of his or her personal data for one or more specific purposes; The right to restriction of processing, as per Article […]
“What Role Is Technology Playing In Helping You Become GDPR Compliant?” We asked this question, (or rather, a version of it) during a survey at our recent GDPR Life Sciences Bootcamp. The respondents were uniformly compliance/transparency professionals from the life sciences industry. Any guesses on what their response was? Less than 10% were able to identify the solution their company uses for GDPR Compliance. An equal number (at 9.09%) said, “No. We are not interested either.” Less than 10% were able to identify the solution their company uses for GDPR Compliance. Bad news, in the light of penalties laid out in the GDPR? Not really, compared to what the other responses were. A little over 27% of respondents acknowledged that […]
Uber recently disclosed a security breach that put the personal data of 57 million users and drivers at risk. As a pharma compliance professional, what does that mean to you, and why should you care? What are the key lessons, and what are its implications for Big Pharma in the post-GDPR environment. Consider all personal data sensitive: In the Uber case, hackers stole names, email addresses and phone numbers, the names and driver’s license numbers of about 600,000 drivers in the United States. Barring license numbers, pharmaceutical companies collect similar data. And for the compliance professionals uninitiated into high-tech data security features, the vulnerabilities can go further. You’re seeing the tip, the iceberg isn’t that far away: News of the […]